PMID: 8581378Oct 1, 1995Paper

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210)

Journal of Hematotherapy
R ReppN Lang

Abstract

Myeloid cells can mediate tumor cell cytotoxicity via certain receptors for immunoglobulins. Among the different Fc receptors, the high-affinity IgG receptor (Fc gamma RI, CD64) is a promising trigger molecule because it is selectively expressed on effector cells, including monocytes/macrophages and granulocyte colony-stimulating factor (G-CSF)-primed neutrophils. In vitro, a bispecific antibody (BsAb) (MDX-210, constructed by chemically cross-linking F(ab') fragments of monoclonal antibody (mAb) 520C9 to HER-2/neu and F(ab') fragments of mAb 22 to Fc gamma RI) mediated effective lysis of HER-2/neu overexpressing breast cancer cell lines. HER-2/neu (c-erbB2) is overexpressed in approximately 30% of breast and ovarian carcinomas and is a target for immunotherapy in clinical trials. In vitro assays showed Fc gamma RI-positive neutrophils to constitute a major effector cell population during G-CSF therapy. Based on these preclinical data and a preceding study at Dartmouth (New Hampshire) with a single dose of MDX-210 alone, a combination of G-CSF and MDX-210 is tested in a phase I study in breast cancer patients. In this study, patients receiving G-CSF are treated with escalating single doses of MDX-210. This therapy was generally...Continue Reading

References

Aug 6, 1992·The New England Journal of Medicine·J R HarrisW Willett
May 11, 1991·Journal of Clinical Immunology·H M ShepardA Ullrich
May 1, 1989·The British Journal of Radiology·W BeckerW Börner
Oct 1, 1983·The Journal of Experimental Medicine·B PerussiaG Trinchieri
May 1, 1993·Immunology Today·J G van de Winkel, P J Capel

❮ Previous
Next ❯

Citations

Jan 1, 1997·International Reviews of Immunology·H RouardJ L Teillaud
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Oct 1, 1995·Journal of Hematotherapy·I A Heijnen, J G Van de Winkel
Aug 30, 2002·The Journal of Biological Chemistry·Jeffrey C EdbergRobert P Kimberly
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur
Oct 1, 1996·Journal of Hematotherapy·A DwengerR Mertelsmann
Dec 18, 2007·Expert Opinion on Biological Therapy·Marjolein van Egmond
Dec 10, 2019·Journal of Pediatric Hematology/oncology·Junichi HaraKiyoshi Yoshimura
Apr 1, 1997·Current Opinion in Immunology·M S HaydenJ A Ledbetter
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.